Opportunity ID: 338827

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-22-076
Funding Opportunity Title: Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Mar 21, 2022
Last Updated Date: Jan 08, 2025
Original Closing Date for Applications: May 07, 2025
Current Closing Date for Applications: Jan 07, 2025
Archive Date: Feb 06, 2025
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: County governments
Special district governments
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Small businesses
City or township governments
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description:

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-22-076.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Version History

Version Modification Description Updated Date
Update close date per reissued NOFO PAR-25-048. Jan 08, 2025
Mar 21, 2022

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-22-076
Funding Opportunity Title: Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Mar 21, 2022
Last Updated Date: Jan 08, 2025
Original Closing Date for Applications: May 07, 2025
Current Closing Date for Applications: Jan 07, 2025
Archive Date: Feb 06, 2025
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: County governments
Special district governments
For profit organizations other than small businesses
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Small businesses
City or township governments
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Private institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description:

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-22-076.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-22-076
Funding Opportunity Title: Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Mar 21, 2022
Last Updated Date: Mar 21, 2022
Original Closing Date for Applications:
Current Closing Date for Applications: May 07, 2025
Archive Date: Jun 12, 2025
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Native American tribal organizations (other than Federally recognized tribal governments)
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Independent school districts
For profit organizations other than small businesses
City or township governments
Private institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
Public housing authorities/Indian housing authorities
Small businesses
Native American tribal governments (Federally recognized)
County governments
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated prospective observational comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-22-076.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email: OERWebmaster03@od.nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Do not use. Must use FORMS-G REVISED form package for all submissions to PAR-22-076 PKG00272693 May 18, 2022 Jun 21, 2022 View
FORMS-G-REVISED Use for due dates on or before January 24, 2023 PKG00275095 Jun 17, 2022 Jan 24, 2023 View
FORMS-H Use for due dates on or before January 24, 2025 PKG00278444 Nov 15, 2022 Jan 09, 2025 View
FORMS-I Use for due dates on or after January 25, 2025 PKG00289206 Nov 27, 2024 Jan 09, 2025 View

Package 1

Mandatory forms

338827 RR_SF424_5_0-5.0.pdf

338827 PHS398_CoverPageSupplement_5_0-5.0.pdf

338827 RR_OtherProjectInfo_1_4-1.4.pdf

338827 PerformanceSite_4_0-4.0.pdf

338827 RR_KeyPersonExpanded_4_0-4.0.pdf

338827 RR_Budget_3_0-3.0.pdf

338827 PHS398_ResearchPlan_4_0-4.0.pdf

338827 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

338827 RR_SubawardBudget30_3_0-3.0.pdf

338827 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

338827 RR_SF424_5_0-5.0.pdf

338827 PHS398_CoverPageSupplement_5_0-5.0.pdf

338827 RR_OtherProjectInfo_1_4-1.4.pdf

338827 PerformanceSite_4_0-4.0.pdf

338827 RR_KeyPersonExpanded_4_0-4.0.pdf

338827 RR_Budget10_3_0-3.0.pdf

338827 PHS398_ResearchPlan_4_0-4.0.pdf

338827 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

338827 RR_SubawardBudget10_30_3_0-3.0.pdf

338827 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

338827 RR_SF424_5_0-5.0.pdf

338827 PHS398_CoverPageSupplement_5_0-5.0.pdf

338827 RR_OtherProjectInfo_1_4-1.4.pdf

338827 PerformanceSite_4_0-4.0.pdf

338827 RR_KeyPersonExpanded_4_0-4.0.pdf

338827 RR_Budget10_3_0-3.0.pdf

338827 PHS398_ResearchPlan_5_0-5.0.pdf

338827 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

338827 RR_SubawardBudget10_30_3_0-3.0.pdf

338827 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 4

Mandatory forms

338827 RR_SF424_5_0-5.0.pdf

338827 PHS398_CoverPageSupplement_5_0-5.0.pdf

338827 RR_OtherProjectInfo_1_4-1.4.pdf

338827 PerformanceSite_4_0-4.0.pdf

338827 RR_KeyPersonExpanded_4_0-4.0.pdf

338827 RR_Budget10_3_0-3.0.pdf

338827 PHS398_ResearchPlan_5_0-5.0.pdf

338827 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

338827 RR_SubawardBudget10_30_3_0-3.0.pdf

338827 PHS_AssignmentRequestForm_4_0-4.0.pdf

2025-07-12T16:55:58-05:00

Share This Post, Choose Your Platform!

About the Author: